Relmada Therapeutics, Inc. RLMD Deferred Tax Assets Nonqualified Stock Option
Deferred Tax Assets Nonqualified Stock Option at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept rlmd:DeferredTaxAssetsNonqualifiedStockOption.
The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s deferred tax assets nonqualified stock option.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s deferred tax assets nonqualified stock option?
- Relmada Therapeutics, Inc. (RLMD) reported deferred tax assets nonqualified stock option of $21.98M in Q4 2025.
- What is the long-term trend for Relmada Therapeutics, Inc.'s deferred tax assets nonqualified stock option?
- Over 2 years (2023 to 2025), Relmada Therapeutics, Inc.'s deferred tax assets nonqualified stock option has grown at a -13.4% compound annual growth rate (CAGR), from $29.31M to $21.98M.
- What does deferred tax assets nonqualified stock option mean?
- This metric captures the deferred tax asset balance generated by the difference between the financial statement expense and the tax deduction associated with nonqualified stock options granted to employees. It represents the future tax savings the company expects to recognize when these options are exercised. This figure is a key indicator of the potential tax shield created by equity-based compensation programs.